BostonGene Announces Publication in Cancer Research

Study Reveals Oncogenic HSP90 Supports Metabolism in B-cell Lymphoma Cells and Patients with Diffuse Large B-cell Lymphoma

WALTHAM, Mass, November 2, 2021

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients today announces a new publication in the peer-reviewed scientific journal Cancer Research, a journal of the American Association for Cancer Research.  The study, performed in collaboration with Weill Cornell Medicine and titled “Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas,” details the role of oncogenic heat shock protein 90 (HSP90) to support metabolic pathways in B-cell lymphoma cells and in patients with diffuse large B-cell lymphoma (DLBCL).

This study evaluated the role of oncogenic HSP90 in regulating cytosolic metabolic pathways in proliferating B-cell lymphoma cells. Oncogenic HSP90 was shown to facilitate the organization of metabolic enzymes into non-membrane-bound functional compartments. BostonGene’s analysis enabled reconstructing the microenvironment in lymphoma expressing a double hit signature, an indicator of aggressive lymphoma with high MYC activity. This analysis showed that alterations to the MYC metabolic program affected immune infiltration, providing insights into improving lymphoma immunity via MYC. It was also observed, under experimental conditions, which conserved cellular proteostasis, oncogenic HSP90 coordinated and sustained multiple metabolic pathways required for energy production and maintenance of cellular biomass as well as for secretion of extracellular metabolites.

“The goal of the study was to further understand metabolic regulation of cellular proteostasis in patients with DLBCL,” said Leandro Cerchietti, M.D., Associate Professor of Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “The encouraging results of this research study demonstrate oncogenic HSP90 is tightly linked to the preservation of cellular biomass providing a novel mechanism of activity for HSP90 inhibitors.”

“These findings underscore the pivotal role of oncogenic HSP90 in the regulation of metabolic pathways in lymphoma, revealing a potential therapeutic vulnerability in B-cell lymphoma,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We are pleased to support Weill Cornell Medicine in their research efforts to find optimal therapeutic treatments for patients with DLBCL.”

About BostonGene Corporation

BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.